NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-10-25 DOI:10.1038/s41571-024-00952-5

Zev A. Wainberg, Eileen M. O’Reilly

引用次数: 0

查看原文本刊更多论文

NALIRIFOX 在转移性胰腺癌一线治疗中的应用：NAPOLI 3 之外的证据

我们饶有兴趣地阅读了 Nevala-Plagemann 和 Garrido-Laguna 撰写的《新闻与观点》（Nevala-Plagemann, C. & Garrido-Laguna, I. NALIRIFOX 治疗转移性胰腺腺癌：希望还是炒作？Nat.Rev. Clin.Oncol.21, 567-568 (2024))1.在这篇文章中，作者对纳米脂质体伊立替康、5-氟尿嘧啶、亮菌素和奥沙利铂（NALIRIFOX）的加入是否构成转移性胰腺导管腺癌（mPDAC）患者治疗方案的真正进展提出了质疑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.